Introduction The English government approved both stages of early medical abortion (EMA), using mifepristone and misoprostol under 10 weeks’ gestation, for at-home use on 30 March 2020. MSI Reproductive Choices UK (MSUK), one of the largest providers of abortion services in England, launched a no-test telemedicine EMA pathway on 6 April 2020. The objectives of this study were to report key patient-reported outcome measures and to assess whether our sample was representative of the whole population receiving no-test telemedicine EMA. Methods A sample of all MSUK’s telemedicine EMA patients between April and August 2020 were invited to opt in to a follow-up call to answer clinical and satisfaction questions. A total of 1243 (13.7% of all telemedicine EMAs) were successfully followed-up, on average within 5 days post-procedure. Results Patients reported high confidence in telemedicine EMA and high satisfaction with the convenience, privacy and ease of managing their abortion at home. The sample responding were broadly equivalent to the whole population receiving telemedicine. No patient reported that they were unable to consult privately. The majority (1035, 83%) of patients reported preferring the telemedicine pathway, with 824 (66%) indicating that they would choose telemedicine again if COVID-19 were no longer an issue. Conclusions Telemedicine EMA is a valued, private, convenient and more accessible option that is highly acceptable for patients seeking an abortion, especially those for whom in-clinic visits are logistically or emotionally challenging. Evidence that this pathway would be a first choice again in future for most patients supports the case to make telemedicine EMA permanent. Data are available upon reasonable request. All data relevant to the study are included in the article or uploaded as supplementary information. Data tables are included within the article. Original raw data are archived on secure servers at MSI Reproductive Choices.

中文翻译：

---

Covid-19 期间通过远程医疗提供的免检测药物流产的可接受性：对患者报告结果的分析

简介 英国政府于 2020 年 3 月 30 日批准了两个阶段的早期药物流产 (EMA)，使用妊娠 10 周以下的米非司酮和米索前列醇在家中使用。MSI Reproductive Choices UK (MSUK)，最大的流产服务提供商之一英国的医疗服务机构于 2020 年 4 月 6 日推出了免测试远程医疗 EMA 途径。本研究的目的是报告患者报告的关键结果指标，并评估我们的样本是否能代表接受免测试远程医疗 EMA 的整个人群。方法 我们邀请 2020 年 4 月至 8 月期间所有 MSUK 远程医疗 EMA 患者作为样本，选择参加后续电话，回答临床和满意度问题。共有 1243 名患者（占所有远程医疗 EMA 的 13.7%）获得成功随访，平均在术后 5 天内完成。结果 患者对远程医疗 EMA 表现出高度信心，并对在家处理堕胎的便利性、隐私性和轻松性表示高度满意。样本响应大致相当于接受远程医疗的全体人群。没有患者报告说他们无法私下咨询。大多数（1035 名，83%）患者表示更喜欢远程医疗途径，其中 824 名（66%）患者表示，如果 COVID-19 不再是问题，他们会再次选择远程医疗。结论 远程医疗 EMA 是一种有价值、私密、方便且更容易获得的选择，对于寻求堕胎的患者来说非常容易接受，特别是对于那些在诊所就诊在后勤或情感上具有挑战性的患者。有证据表明，这条途径将在未来再次成为大多数患者的首选，这支持了使远程医疗 EMA 永久化的理由。数据可根据合理要求提供。与研究相关的所有数据都包含在文章中或作为补充信息上传。数据表包含在文章中。原始原始数据存档在 MSI Reproductive Choices 的安全服务器上。